Preclinical studies and the function of IL-17 cytokines in COPD

Felix Ritzmann; Christoph Beisswenger

doi:10.1016/j.aanat.2021.151729

Preclinical studies and the function of IL-17 cytokines in COPD

Ann Anat. 2021 Sep:237:151729. doi: 10.1016/j.aanat.2021.151729. Epub 2021 Mar 30.

Authors

Felix Ritzmann¹, Christoph Beisswenger²

Affiliations

¹ Department of Internal Medicine V - Pulmonology, Allergology and Respiratory Critical Care Medicine, Saarland University, 66421 Homburg, Germany.
² Department of Internal Medicine V - Pulmonology, Allergology and Respiratory Critical Care Medicine, Saarland University, 66421 Homburg, Germany. Electronic address: christoph.beisswenger@uks.eu.

PMID: 33798693
DOI: 10.1016/j.aanat.2021.151729

Abstract

Chronic obstructive pulmonary disease (COPD) is among the leading causes of death worldwide and imposes a high economic burden to the health systems. COPD is characterized by chronic inflammation of the lung leading to airflow limitation, alveolar tissue destruction, and emphysema. Therefore, anti-inflammatory therapies for the treatment of COPD are of interest. In this review, we focus on the function of the IL-17 cytokines IL-17A and IL-17C, both known to mediate the recruitment of inflammatory cells, in the pathogenesis of COPD. We highlight that the expression of IL-17A and IL-17C is induced by pathogens frequently found in lungs of COPD patients and that targeting IL-17-signaling is an interesting option for the treatment of acute exacerbation of COPD.

Keywords: COPD; IL-17A; IL-17C; Inflammation; Lung damage.

Publication types

Review

MeSH terms

Animals
Cytokines
Humans
Interleukin-17*
Lung
Mice
Mice, Inbred C57BL
Pulmonary Disease, Chronic Obstructive*

Substances

Cytokines
Interleukin-17